Metabolism-Clinical and Experimental

Papers
(The median citation count of Metabolism-Clinical and Experimental is 1. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)
ArticleCitations
Severe obesity, increasing age and male sex are independently associated with worse in-hospital outcomes, and higher in-hospital mortality, in a cohort of patients with COVID-19 in the Bronx, New York604
Obesity in patients with COVID-19: a systematic review and meta-analysis318
Complications, morbidity and mortality of nonalcoholic fatty liver disease260
A 2022 update on the epidemiology of obesity and a call to action: as its twin COVID-19 pandemic appears to be receding, the obesity and dysmetabolism pandemic continues to rage on246
Letter to the Editor: Obesity as a risk factor for greater severity of COVID-19 in patients with metabolic associated fatty liver disease242
Insulin resistance, cardiovascular stiffening and cardiovascular disease229
The role of peroxisome proliferator-activated receptors (PPAR) in immune responses225
MAFLD and risk of CKD173
Commentary: Obesity: The “Achilles heel” for COVID-19?158
Role of the gut microbiota in type 2 diabetes and related diseases150
Visceral fat shows the strongest association with the need of intensive care in patients with COVID-19147
The role of visceral adiposity in the severity of COVID-19: Highlights from a unicenter cross-sectional pilot study in Germany136
The link between COVID-19 and VItamin D (VIVID): A systematic review and meta-analysis134
Insights into the molecular targets and emerging pharmacotherapeutic interventions for nonalcoholic fatty liver disease133
Commentary: Testosterone, a key hormone in the context of COVID-19 pandemic133
Letter to the Editor: Low-density lipoprotein is a potential predictor of poor prognosis in patients with coronavirus disease 2019122
Commentary: COVID-19 in patients with diabetes121
Non-alcoholic fatty liver disease, insulin resistance, metabolic syndrome and their association with vascular risk102
Letter to the Editor: Diabetes patients with COVID-19 need better blood glucose management in Wuhan, China99
Association of body mass index (BMI) with critical COVID-19 and in-hospital mortality: A dose-response meta-analysis95
Visceral fat is associated to the severity of COVID-1995
Metformin: Is it a drug for all reasons and diseases?94
The serum metabolome of COVID-19 patients is distinctive and predictive91
Metabolic liver disease in diabetes – From mechanisms to clinical trials88
Current and emerging pharmacological options for the treatment of nonalcoholic steatohepatitis87
Insulin resistance and insulin sensitizing agents84
Current trends in epidemiology of cardiovascular disease and cardiovascular risk management in type 2 diabetes82
Heart failure in diabetes79
Insulin: The master regulator of glucose metabolism77
Epidemiology of sarcopenia: Prevalence, risk factors, and consequences74
Inhibition of NLRP3 inflammasome ameliorates podocyte damage by suppressing lipid accumulation in diabetic nephropathy73
Letter to the Editor: COVID-19 in patients with diabetes: Risk factors that increase morbidity70
The effect of underweight on female and male reproduction69
FUNDC1 insufficiency sensitizes high fat diet intake-induced cardiac remodeling and contractile anomaly through ACSL4-mediated ferroptosis67
The role of omics in the pathophysiology, diagnosis and treatment of non-alcoholic fatty liver disease65
The effect of the magnitude of weight loss on non-alcoholic fatty liver disease: A systematic review and meta-analysis62
Impact of antidiabetic agents on dementia risk: A Bayesian network meta-analysis62
Mediterranean diet as a nutritional approach for COVID-1962
Bile acids profile, histopathological indices and genetic variants for non-alcoholic fatty liver disease progression62
Commentary: COVID-19 and diabetes mellitus: What we know, how our patients should be treated now, and what should happen next60
Diabetes and COVID-19: The past, the present, and the future59
Association of obesity and its genetic predisposition with the risk of severe COVID-19: Analysis of population-based cohort data59
Letter to the Editor: Vitamin D deficiency in COVID-19: Mixing up cause and consequence58
Mitochondrial dynamics and nonalcoholic fatty liver disease (NAFLD): new perspectives for a fairy-tale ending?58
Impact of body composition on COVID-19 susceptibility and severity: A two-sample multivariable Mendelian randomization study57
Commentary: Could iron chelators prove to be useful as an adjunct to COVID-19 Treatment Regimens?57
Kidney disease in diabetes: From mechanisms to clinical presentation and treatment strategies54
Activation of TRPV1 channel antagonizes diabetic nephropathy through inhibiting endoplasmic reticulum-mitochondria contact in podocytes53
Factors affecting weight loss variability in obesity50
A new mechanism of obeticholic acid on NASH treatment by inhibiting NLRP3 inflammasome activation in macrophage50
The effect of excess body fat on female and male reproduction50
Empagliflozin improves diabetic renal tubular injury by alleviating mitochondrial fission via AMPK/SP1/PGAM5 pathway49
Commentary: Phosphodiesterase 4 inhibitors as potential adjunct treatment targeting the cytokine storm in COVID-1949
FOS/GOS attenuates high-fat diet induced bone loss via reversing microbiota dysbiosis, high intestinal permeability and systemic inflammation in mice49
Statin use is associated with lower prevalence of advanced liver fibrosis in patients with type 2 diabetes47
Epicardial adipose tissue is associated with extent of pneumonia and adverse outcomes in patients with COVID-1947
Myocardial ketone body utilization in patients with heart failure: The impact of oral ketone ester47
PCSK9 Inhibition with alirocumab increases the catabolism of lipoprotein(a) particles in statin-treated patients with elevated lipoprotein(a)46
Commentary: Nonalcoholic or metabolic dysfunction-associated fatty liver disease? The epidemic of the 21st century in search of the most appropriate name45
Mitochondrial quality control mechanisms as molecular targets in diabetic heart44
Effect of alternate-day fasting on obesity and cardiometabolic risk: A systematic review and meta-analysis44
UCP1-dependent and UCP1-independent metabolic changes induced by acute cold exposure in brown adipose tissue of mice43
METTL3 is required for maintaining β-cell function43
Preadmission use of antidiabetic medications and mortality among patients with COVID-19 having type 2 diabetes: A meta-analysis43
Commentary: Myths and facts on vitamin D amidst the COVID-19 pandemic42
Transition of acute kidney injury to chronic kidney disease: role of metabolic reprogramming42
Fenofibrate, a PPARα agonist, reduces hepatic fat accumulation through the upregulation of TFEB-mediated lipophagy42
Cardiorenal protection with SGLT2 inhibitors in patients with diabetes mellitus: from biomarkers to clinical outcomes in heart failure and diabetic kidney disease41
Moderate alcohol consumption is associated with advanced fibrosis in non-alcoholic fatty liver disease and shows a synergistic effect with type 2 diabetes mellitus40
Letter to the Editor: Mental Health and Psychological Distress in People with Diabetes during COVID-1940
Legacy effect of intensive glucose control on major adverse cardiovascular outcome: Systematic review and meta-analyses of trials according to different scenarios40
Lipids activate skeletal muscle mitochondrial fission and quality control networks to induce insulin resistance in humans40
Regulation of NAD+ metabolism in aging and disease39
Mitochondrial dysfunction in diabetic tubulopathy39
Advances in biological therapies for dyslipidemias and atherosclerosis39
Dapagliflozin promotes beta cell regeneration by inducing pancreatic endocrine cell phenotype conversion in type 2 diabetic mice38
Beclin1 haploinsufficiency rescues low ambient temperature-induced cardiac remodeling and contractile dysfunction through inhibition of ferroptosis and mitochondrial injury38
Commentary: Statins, COVID-19, and coronary artery disease: killing two birds with one stone38
Sodium/glucose cotransporter 2 (SGLT2) inhibitors improve cardiac function by reducing JunD expression in human diabetic hearts37
Advances in non-invasive biomarkers for the diagnosis and monitoring of non-alcoholic fatty liver disease37
The global syndemic of metabolic diseases in the young adult population: A consortium of trends and projections from the Global Burden of Disease 2000–201936
Functions of amyloid precursor protein in metabolic diseases36
Established and emerging factors affecting the progression of nonalcoholic fatty liver disease35
Targeting mammalian serine/threonine-protein kinase 4 through Yes-associated protein/TEA domain transcription factor-mediated epithelial-mesenchymal transition ameliorates diabetic nephropathy orchest35
Pharmacotherapy of type 2 diabetes: An update and future directions35
Cardiovascular outcomes trials with incretin-based medications: a critical review of data available on GLP-1 receptor agonists and DPP-4 inhibitors35
Metabolic dysfunction–associated fatty liver disease and the risk of 24 specific cancers34
Schisandrin B mitigates hepatic steatosis and promotes fatty acid oxidation by inducing autophagy through AMPK/mTOR signaling pathway34
Muscle area and density and risk of all-cause mortality: The Multi-Ethnic Study of Atherosclerosis34
Letter to the editor: Unexpected high mortality in COVID-19 and diabetic ketoacidosis34
Deacetylation of Caveolin-1 by Sirt6 induces autophagy and retards high glucose-stimulated LDL transcytosis and atherosclerosis formation34
Diabetes, glycaemic control, and risk of COVID-19 hospitalisation: Population-based, prospective cohort study33
Machine learning and semi-targeted lipidomics identify distinct serum lipid signatures in hospitalized COVID-19-positive and COVID-19-negative patients32
Diabetes and kidney disease: emphasis on treatment with SGLT-2 inhibitors and GLP-1 receptor agonists32
The presence of NAFLD influences the transition of metabolically healthy to metabolically unhealthy obesity and the ten-year cardiovascular disease risk: A population-based cohort study32
SARS-CoV-2 infection impairs the insulin/IGF signaling pathway in the lung, liver, adipose tissue, and pancreatic cells via IRF131
FNDC4, a novel adipokine that reduces lipogenesis and promotes fat browning in human visceral adipocytes31
C C chemokine ligand 3 deficiency ameliorates diet-induced steatohepatitis by regulating liver macrophage recruitment and M1/M2 status in mice31
Non-obese non-alcoholic fatty liver disease (NAFLD) in Asia: an international registry study30
Type VI collagen and its cleavage product, endotrophin, cooperatively regulate the adipogenic and lipolytic capacity of adipocytes30
Post-transplant obesity impacts long-term survival after liver transplantation29
Hrd1-mediated ACLY ubiquitination alleviate NAFLD in db/db mice29
Cholesterol induced autophagy via IRE1/JNK pathway promotes autophagic cell death in heart tissue29
Exosomes: Advances, development and potential therapeutic strategies in diabetic nephropathy29
Making progress in nonalcoholic fatty liver disease (NAFLD) as we are transitioning from the era of NAFLD to dys-metabolism associated fatty liver disease (DAFLD)28
Disrupted endothelial cell heterogeneity and network organization impair vascular function in prediabetic obesity28
PINK1–PRKN mitophagy suppression by mangiferin promotes a brown-fat-phenotype via PKA-p38 MAPK signalling in murine C3H10T1/2 mesenchymal stem cells28
Diet and exercise reduce pre-existing NASH and fibrosis and have additional beneficial effects on the vasculature, adipose tissue and skeletal muscle via organ-crosstalk27
Epigenetic modifications in diabetes27
CT-derived abdominal adiposity: Distributions and better predictive ability than BMI in a nationwide study of 59,429 adults in China27
Commentary: COVID-19 and obesity pandemics converge into a syndemic requiring urgent and multidisciplinary action27
Basal weekly insulins: the way of the future!27
11β-hydroxysteroid dehydrogenase type 1 inhibitor use in human disease-a systematic review and narrative synthesis27
Nonalcoholic fatty liver disease and cardiovascular diseases: A Mendelian randomization study27
Revealing the role of peroxisome proliferator-activated receptor β/δ in nonalcoholic fatty liver disease26
Commentary. Eliminating vitamin D deficiency during the COVID-19 pandemic: A call to action26
Diabetes and metabolic dysfunction-associated fatty liver disease26
The impact of hyperglycaemia on PKM2-mediated NLRP3 inflammasome/stress granule signalling in macrophages and its correlation with plaque vulnerability: an in vivo and in vitro study26
Bone morphogenetic proteins (BMPs) in the central regulation of energy balance and adult neural plasticity26
The role of serum adipokine levels in preeclampsia: A systematic review26
Exercise timing influences multi-tissue metabolome and skeletal muscle proteome profiles in type 2 diabetic patients – A randomized crossover trial25
Preparing for the NASH epidemic: A call to action25
Perturbation of the circadian clock and pathogenesis of NAFLD25
A multi-omic analysis of birthweight in newborn cord blood reveals new underlying mechanisms related to cholesterol metabolism25
Dietary carbohydrate intake and new-onset diabetes: A nationwide cohort study in China25
Body fatness associations with cancer: evidence from recent epidemiological studies and future directions25
Hepatic insulin-degrading enzyme regulates glucose and insulin homeostasis in diet-induced obese mice25
Excess body weight is an independent risk factor for severe forms of COVID-1925
Functional loss of pancreatic islets in type 2 diabetes: How can we halt it?25
Metformin and the heart: Update on mechanisms of cardiovascular protection with special reference to comorbid type 2 diabetes and heart failure24
Lipoprotein (a) and coronary artery calcification: prospective study assessing interactions with other risk factors24
TBC1D15-Drp1 interaction-mediated mitochondrial homeostasis confers cardioprotection against myocardial ischemia/reperfusion injury23
SGLT2-inhibitors reduce the cardiac autonomic neuropathy dysfunction and vaso-vagal syncope recurrence in patients with type 2 diabetes mellitus: the SCAN study23
Letter to the Editor: Obesity hypoventilation syndrome and severe COVID-1923
The IL-8-CXCR1/2 axis contributes to diabetic kidney disease23
Synergistic effects of fructose and glucose on lipoprotein risk factors for cardiovascular disease in young adults22
The progression and regression of metabolic dysfunction-associated fatty liver disease are associated with the development of subclinical atherosclerosis: A prospective analysis22
Letter to the Editor: Obesity as a risk factor for greater severity of COVID-19 in patients with metabolic associated fatty liver disease22
A novel Sprouty4-ERK1/2-Wnt/β-catenin regulatory loop in marrow stromal progenitor cells controls osteogenic and adipogenic differentiation22
Pioglitazone corrects dysregulation of skeletal muscle mitochondrial proteins involved in ATP synthesis in type 2 diabetes22
Metabolic impact of weight loss induced reduction of adipose ACE-2 – Potential implication in COVID-19 infections?22
The protein S100A4 as a novel marker of insulin resistance in prepubertal and pubertal children with obesity22
Thromboembolism risk among patients with diabetes/stress hyperglycemia and COVID-1922
Letter to the Editor: Importance of metabolic health in the era of COVID-1922
Cancer causes metabolic perturbations associated with reduced insulin-stimulated glucose uptake in peripheral tissues and impaired muscle microvascular perfusion22
Higd1a facilitates exercise-mediated alleviation of fatty liver in diet-induced obese mice22
Twelve weeks of exenatide treatment increases [18F]fluorodeoxyglucose uptake by brown adipose tissue without affecting oxidative resting energy expenditure in nondiabetic males21
Early adaptive thermogenesis is a determinant of weight loss after six weeks of caloric restriction in overweight subjects21
ApoCIII: A multifaceted protein in cardiometabolic disease21
commentary: COVID-19 and Obesity: Exploring Biologic Vulnerabilities, Structural Disparities, and Weight Stigma21
Hyperglycemia-reduced NAD+ biosynthesis impairs corneal epithelial wound healing in diabetic mice21
Maternal high-fat high-sucrose diet and gestational exercise modulate hepatic fat accumulation and liver mitochondrial respiratory capacity in mothers and male offspring21
Management of diabetic neuropathy20
The effect of dietary patterns on non-alcoholic fatty liver disease diagnosed by biopsy or magnetic resonance in adults: a systematic review of randomised controlled trials20
Ubiquitination of PPAR-gamma by pVHL inhibits ACLY expression and lipid metabolism, is implicated in tumor progression20
SGLT-2 inhibitors as cardio-renal protective agents20
Intestine-liver crosstalk in Type 2 Diabetes and non-alcoholic fatty liver disease20
CX3CL1/CX3CR1 interaction protects against lipotoxicity-induced nonalcoholic steatohepatitis by regulating macrophage migration and M1/M2 status20
Use of imaging techniques for non-invasive assessment in the diagnosis and staging of non-alcoholic fatty liver disease20
cAMP-response element binding protein mediates podocyte injury in diabetic nephropathy by targeting lncRNA DLX6-AS119
Non-alcoholic fatty liver disease, metabolic goal achievement with incident cardiovascular disease and eGFR-based chronic kidney disease in patients with prediabetes and diabetes19
The MafA-target gene PPP1R1A regulates GLP1R-mediated amplification of glucose-stimulated insulin secretion in β-cells19
High-density lipoprotein characteristics and coronary artery disease: a Mendelian randomization study19
Incretin-based therapies in 2021 – Current status and perspectives for the future19
Sustained mitochondrial biogenesis is essential to maintain caloric restriction-induced beige adipocytes19
Decreased microRNA-125b-5p disrupts follicle steroidogenesis through targeting PAK3/ERK1/2 signalling in mouse preantral follicles19
Vascular smooth muscle cell c-Fos is critical for foam cell formation and atherosclerosis19
Changing trends of liver transplantation and mortality from non-alcoholic fatty liver disease19
Nonalcoholic fatty liver disease increases the risk of diabetes in young adults: A nationwide population-based study in Korea19
Myeloid-specific IRE1alpha deletion reduces tumour development in a diabetic, non-alcoholic steatohepatitis-induced hepatocellular carcinoma mouse model19
The efficacy and safety of dipeptidyl peptidase-4 inhibitors compared to other oral glucose-lowering medications in the treatment of type 2 diabetes19
Artificial intelligence and diabetes technology: A review18
Sodium-glucose cotransporter 2 inhibition attenuates protein overload in renal proximal tubule via suppression of megalin O-GlcNacylation in progressive diabetic nephropathy18
Association of fatty liver index with all-cause and disease-specific mortality: A nationwide cohort study18
Loss of iRhom2 accelerates fat gain and insulin resistance in diet-induced obesity despite reduced adipose tissue inflammation18
Extra-skeletal effects of bisphosphonates18
Loss of postprandial insulin clearance control by Insulin-degrading enzyme drives dysmetabolism traits18
Association of class number, cumulative exposure, and earlier initiation of antibiotics during the first two-years of life with subsequent childhood obesity18
Glucose transporter 3 in neuronal glucose metabolism: Health and diseases18
Diabetic ketoacidosis in pediatric patients with type 1- and type 2 diabetes during the COVID-19 pandemic18
Apolipoprotein C3 aggravates diabetic nephropathy in type 1 diabetes by activating the renal TLR2/NF-κB pathway18
Tricarboxylic acid cycle related-metabolites and risk of atrial fibrillation and heart failure18
Deletion of BCATm increases insulin-stimulated glucose oxidation in the heart18
Pharmacological activation of REV-ERBα improves nonalcoholic steatohepatitis by regulating intestinal permeability18
Editorial: Obesity, metabolic phenotypes and COVID-1918
Among simple non-invasive scores, Pro-C3 and ADAPT best exclude advanced fibrosis in Asian patients with MAFLD18
Adiponectin promotes repair of renal tubular epithelial cells by regulating mitochondrial biogenesis and function17
Use of incretin-based medications: what do current international recommendations suggest with respect to GLP-1 receptor agonists and DPP-4 inhibitors?17
Risk of incident diabetes after COVID-19 infection: A systematic review and meta-analysis17
Beyond mitochondria: Alternative energy-producing pathways from all strata of life17
Altered metabolic and hormonal responses to moderate exercise in overweight/obesity17
Recent advances in closed-loop insulin delivery17
Effectiveness of dulaglutide vs liraglutide and exenatide once-weekly. A real-world study and meta-analysis of observational studies17
Increased AMP deaminase activity decreases ATP content and slows protein degradation in cultured skeletal muscle17
Identification of a novel leptin receptor (LEPR) variant and proof of functional relevance directing treatment decisions in patients with morbid obesity17
GW9662, a peroxisome proliferator-activated receptor gamma antagonist, attenuates the development of non-alcoholic fatty liver disease17
AMP-activated protein kinase (AMPK) signaling in GnRH neurons links energy status and reproduction16
Effects of aerobic exercise on fibroblast growth factor 21 in overweight and obesity. A systematic review16
Histone methyltransferases G9a mediated lipid-induced M1 macrophage polarization through negatively regulating CD3616
Mendelian randomization study of obesity and type 2 diabetes in hospitalized COVID-19 patients16
AMP deamination is sufficient to replicate an atrophy-like metabolic phenotype in skeletal muscle16
ApoC2 deficiency elicits severe hypertriglyceridemia and spontaneous atherosclerosis: A rodent model rescued from neonatal death16
TMBIM6 prevents VDAC1 multimerization and improves mitochondrial quality control to reduce sepsis-related myocardial injury16
Inhibition of miR-153, an IL-1β-responsive miRNA, prevents beta cell failure and inflammation-associated diabetes16
Thiazolidinediones, alpha-glucosidase inhibitors, meglitinides, sulfonylureas, and hepatocellular carcinoma risk: A meta-analysis16
Adiponectin's mechanisms in high-density lipoprotein biogenesis and cholesterol efflux16
The β-cell glucose toxicity hypothesis: Attractive but difficult to prove16
Time trends and predictors of hypovitaminosis D across the life course: 2009–201615
IDH1-dependent α-KG regulates brown fat differentiation and function by modulating histone methylation15
YY1 deficiency in β-cells leads to mitochondrial dysfunction and diabetes in mice15
Letter to the Editor: Mechanisms of increased morbidity and mortality of SARS-CoV-2 infection in individuals with diabetes: what this means for an effective management strategy15
Associations of abdominal muscle area and density with coronary artery calcium volume and density: The multi-ethnic study of atherosclerosis15
Brown adipose tissue transplantation ameliorates diabetic nephropathy through the miR-30b pathway by targeting Runx115
Dissecting causal relationships between nonalcoholic fatty liver disease proxied by chronically elevated alanine transaminase levels and 34 extrahepatic diseases15
Circulating α-klotho regulates metabolism via distinct central and peripheral mechanisms15
FGF21 and Chronic Kidney Disease15
Sarcopenia, osteoporosis and frailty15
Association of prediabetes, diabetes, and diabetes duration with biliary tract cancer risk: A nationwide cohort study15
Mebhydrolin ameliorates glucose homeostasis in type 2 diabetic mice by functioning as a selective FXR antagonist14
Sarcopenia in youth14
Inhibiting glycolysis rescues memory impairment in an intellectual disability Gdi1-null mouse14
Laminins in metabolic tissues14
Recent guidelines for Non-Alcoholic Fatty Liver disease (NAFLD)/ Fatty Liver Disease (FLD): Are they already outdated and in need of supplementation?14
Defects in High Density Lipoprotein metabolism and hepatic steatosis in mice with liver-specific ablation of Hepatocyte Nuclear Factor 4A14
Urinary GC–MS steroid metabotyping in treated children with congenital adrenal hyperplasia.14
Systematic review with meta-analysis of diagnostic test accuracy for COVID-19 by mass spectrometry14
Early humoral response to COVID-19 vaccination in patients living with obesity and diabetes in France. The COVPOP OBEDIAB study with results from the ANRS0001S COV-POPART cohort14
Fasting glucagon concentrations are associated with longitudinal decline of β-cell function in non-diabetic humans14
A requirement for PAK1 to support mitochondrial function and maintain cellular redox balance via electron transport chain proteins to prevent β-cell apoptosis14
From non-alcoholic fatty liver disease (NAFLD) to steatotic liver disease (SLD): an ongoing journey towards refining the terminology for this prevalent metabolic condition and unmet clinical need14
Elafibranor improves diet-induced nonalcoholic steatohepatitis associated with heart failure with preserved ejection fraction in Golden Syrian hamsters14
Taurine treatment reverses protein malnutrition-induced endothelial dysfunction of the pancreatic vasculature: The role of hydrogen sulfide14
miRNA-22 deletion limits white adipose expansion and activates brown fat to attenuate high-fat diet-induced fat mass accumulation14
AGEs exacerbates coronary microvascular dysfunction in NoCAD by activating endoplasmic reticulum stress-mediated PERK signaling pathway14
Elevated FURIN levels in predicting mortality and cardiovascular events in patients with acute myocardial infarction13
PTC923 (sepiapterin) lowers elevated blood phenylalanine in subjects with phenylketonuria: a phase 2 randomized, multi-center, three-period crossover, open-label, active controlled, all-comers study13
Endothelial sodium channel activation promotes cardiac stiffness and diastolic dysfunction in Western diet fed female mice13
Novel metabolic classification for extrahepatic complication of metabolic associated fatty liver disease: A data-driven cluster analysis with international validation13
Metformin-induced TTP mediates communication between Kupffer cells and hepatocytes to alleviate hepatic steatosis by regulating lipophagy and necroptosis13
Lipoprotein (a)-mediated vascular calcification: population-based and in vitro studies13
Downregulation of NK cell activities in Apolipoprotein C-III-induced hyperlipidemia resulting from lipid-induced metabolic reprogramming and crosstalk with lipid-laden dendritic cells13
Comprehensive molecular mechanisms and clinical therapy in nonalcoholic steatohepatitis: An overview and current perspectives13
SLC46A1 contributes to hepatic iron metabolism by importing heme in hepatocytes13
Role of apolipoprotein E in electronegative low-density lipoprotein-induced mitochondrial dysfunction in cardiomyocytes13
Adipose tissue adipokines and lipokines: Functions and regulatory mechanism in skeletal muscle development and homeostasis13
The S100 calcium-binding protein A11 promotes hepatic steatosis through RAGE-mediated AKT-mTOR signaling13
Absence of AGPAT2 impairs brown adipogenesis, increases IFN stimulated gene expression and alters mitochondrial morphology13
Insights on the molecular targets of cardiotoxicity induced by anticancer drugs: A systematic review based on proteomic findings12
LPS-enriched small extracellular vesicles from metabolic syndrome patients trigger endothelial dysfunction by activation of TLR412
The clustering of Cardiovascular, Renal, Adipo-Metabolic Eye and Liver disease with type 2 diabetes12
0.027292966842651